工程化益生菌用于肿瘤靶向联合化学免疫治疗
Engineered probiotics for tumor-targeted combination chemoimmunotherapy.
我们的方法将酶/前药治疗和免疫治疗整合到一个单一的细菌递送系统中,通过提供合理设计的空间控制化学免疫治疗框架,克服了传统疗法的关键局限性。
英文原题:Tumor-microenvironment-modulating microspheres to augment tumor-infiltrating lymphocyte therapy against solid tumors.
TIL(肿瘤浸润淋巴细胞)疗法是一种获批用于治疗实体瘤的 T 细胞疗法。
TIL(肿瘤浸润淋巴细胞)疗法是一种已获批用于实体瘤的 T 细胞疗法。然而,致密的细胞外基质(ECM)和免疫抑制性肿瘤微环境(TME)会导致初次采集的 TIL 数量和活性受限,进而使制备过程耗时且治疗效果不理想。本研究开发了共同负载透明质酸酶(HAase)和趋化因子 CXCL9 的海藻酸盐水凝胶微球。瘤内注射后,微球释放 HAase 降解 ECM,并释放 CXCL9 募集淋巴细胞浸润,从而有效调节 TME,显著增加肿瘤内 TIL 数量。从这些预处理肿瘤中采集的 TIL 不仅体外扩增加快,活性和抗耗竭能力也明显改善。回输这些 TIL 后,可在不同肿瘤模型中显著抑制肿瘤生长和转移。本研究表明,在采集肿瘤前调节 TME,可能是增强现有 TIL 疗法的有效且具有临床可行性的策略。
Tumor-infiltrating lymphocyte (TIL) therapy is a T cell therapy approved for treating solid tumors. However, the dense extracellular matrix (ECM) and immunosuppressive tumor microenvironment (TME) result in limited numbers and activities of initially harvested TILs, further leading to time-consuming preparation processes and suboptimal treatment efficacy. Herein, we develop alginate-based hydrogel microspheres co-loaded with hyaluronidase (HAase) and chemokine CXCL9. With released HAase to degrade the extracellular matrix and CXCL9 to recruit lymphocyte infiltration, such microspheres after intratumoral injection allow effective TME modulation, leading to greatly enhanced TIL numbers in tumors. TILs collected from those pre-treated tumors exhibit not only accelerated ex vivo expansion but also markedly improved activities and anti-exhaustion capacities. Those TILs after re-infusion could significantly inhibit tumor growths and metastases in different tumor models. Our work demonstrates that modulating TME before tumor collection may be an effective and clinically practical approach to boost current TIL therapies.
MEMBER ACCOUNT
登录成功会直接打开下一页。